

TABLE OF CONTENTS

0. Executive Summary	16
1. Basics of Proteomics.....	18
Introduction	18
History.....	18
Nucleic acids, genes and proteins	19
Genome.....	19
DNA	20
RNA	20
<i>MicroRNAs</i>	<i>20</i>
<i>Decoding of mRNA by the ribosome</i>	<i>21</i>
Genes.....	22
Alternative splicing.....	22
Transcription.....	23
Gene regulation	23
Gene expression	24
Chromatin.....	24
Golgi complex.....	25
Proteins.....	25
<i>Spliceosome.....</i>	<i>26</i>
<i>Functions of proteins</i>	<i>26</i>
<i>Inter-relationship of protein, mRNA and DNA.....</i>	<i>27</i>
Proteomics.....	28
Mitochondrial proteome	29
<i>S-nitrosoproteins in mitochondria</i>	<i>29</i>
Proteomics and genomics	30
Classification of proteomics	32
Levels of functional genomics and various "omics"	32
Glycoproteomics	33
Transcriptomics	33
Metabolomics	33
Cytomics.....	34
Phenomics	34
Proteomics and systems biology.....	34
Functional synthetic proteins.....	35
2. Proteomic Technologies.....	36
Key technologies driving proteomics	36
Sample preparation	37
New trends in sample preparation.....	37
Pressure Cycling Technology	38
Protein separation technologies	38
High resolution 2D gel electrophoresis	38
Variations of 2D gel technology	39
Limitations of 2DGE and measures to overcome these	39
1-D sodium dodecyl sulfate (SDS) PAGE	39
Capillary electrophoresis systems.....	40
Head column stacking capillary zone electrophoresis	40
Removal of albumin and IgG	40
Companies with protein separation technologies	41
Protein detection	42
Protein identification and characterization	43
Mass spectrometry (MS)	43
<i>Companies involved in mass spectrometry</i>	<i>43</i>
<i>Electrospray ionization.....</i>	<i>44</i>
<i>Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry</i>	<i>45</i>
<i>Cryogenic MALDI- Fourier Transform Mass Spectrometry</i>	<i>46</i>
<i>Stable-isotope-dilution tandem mass spectrometry</i>	<i>47</i>
<i>HUPO Gold MS Protein Standard</i>	<i>47</i>
High performance liquid chromatography	47
Multidimensional protein identification technology (MudPIT)	48
Peptide mass fingerprinting	48
Combination of protein separation technologies with mass spectrometry.....	48
<i>Combining capillary electrophoresis with mass spectrometry</i>	<i>48</i>
<i>2D PAGE and mass spectrometry</i>	<i>49</i>
<i>Quantification of low abundance proteins</i>	<i>49</i>
<i>SDS-PAGE.....</i>	<i>49</i>

Antibodies and proteomics	50
Detection of fusion proteins.....	50
Labeling and detection of proteins.....	50
<i>Fluorescent labeling of proteins in living cells.....</i>	<i>51</i>
<i>Combination of microspheres with fluorescence</i>	<i>51</i>
<i>Self-labeling protein tags</i>	<i>52</i>
Analysis of peptides	52
<i>C-terminal peptide analysis.....</i>	<i>53</i>
<i>Differential Peptide Display</i>	<i>53</i>
<i>Peptide analyses using NanoLC-MS</i>	<i>54</i>
Protein sequencing	54
Real-time PCR for protein quantification.....	55
Quantitative proteomics	55
MS-based quantitative proteomics	55
MS and cryo-electron tomography.....	56
Functional proteomics: technologies for studying protein function.....	56
Functional genomics by mass spectrometry.....	56
RNA-Protein fusions	56
Designed repeat proteins.....	57
Application of nanobiotechnology to proteomics	57
Nanoproteomics.....	57
<i>Protein nanocrystallography</i>	<i>58</i>
<i>Single-molecule mass spectrometry using a nanopore</i>	<i>58</i>
<i>Nanoelectrospray ionization.....</i>	<i>58</i>
Nanoparticle barcodes	59
<i>Biobarcode assay for proteins.....</i>	<i>59</i>
Nanobiotechnology for discovery of protein biomarkers in the blood	61
Nanoscale protein analysis	61
Nanoscale mechanism for protein engineering	62
Nanotube electronic biosensor	62
Nanotube-vesicle networks for study of membrane proteins	63
Nanowire transistor for the detection of protein-protein interactions.....	63
Qdot-nanocrystals.....	63
Resonance Light Scattering technology	64
Study of single membrane proteins at subnanometer resolution	64
Protein expression profiling.....	64
Cell-based protein assays	65
Living cell-based assays for protein function.....	66
Companies developing cell-based protein assays.....	66
Protein function studies.....	67
Transcriptionally Active PCR	67
Protein-protein interactions	67
<i>Yeast two-hybrid system.....</i>	<i>69</i>
<i>Membrane one-hybrid method.....</i>	<i>70</i>
<i>Protein affinity chromatography.....</i>	<i>70</i>
<i>Phage display</i>	<i>70</i>
<i>Fluorescence Resonance Energy Transfer.....</i>	<i>71</i>
<i>Bioluminescence Resonance Energy Transfer.....</i>	<i>71</i>
<i>Detection Enhanced Ubiquitin Split Protein Sensor technology</i>	<i>71</i>
<i>Protein-fragment complementation system</i>	<i>72</i>
<i>In vivo study of protein-protein interactions</i>	<i>72</i>
<i>Computational prediction of interactions</i>	<i>73</i>
<i>Interactome</i>	<i>73</i>
<i>Protein-protein interactions and drug discovery</i>	<i>74</i>
<i>Companies with technologies for protein-protein interaction studies</i>	<i>74</i>
Protein-DNA interaction	75
Determination of protein structure	75
X-Ray crystallography	76
Nuclear magnetic resonance.....	77
Electron spin resonance	77
Prediction of protein structure	77
Protein tomography.....	78
X-ray scattering-based method for determining the structure of proteins	79
Prediction of protein function	79
Three-dimensional proteomics for determination of function.....	80
An algorithm for genome-wide prediction of protein function	80
Monitoring protein function by expression profiling.....	80
Isotope-coded affinity tag peptide labeling	81
Differential Proteomic Panning	81
Cell map proteomics	82
Topological proteomics.....	82

Organelle or subcellular proteomics	83
Nucleolar proteomics	83
Glycoproteomic technologies	84
High-sensitivity glycoprotein analysis	84
Fluorescent in vivo imaging of glycoproteins.....	84
Integrated approaches for protein characterization	84
Imaging mass spectrometry	85
IMS technologies	85
Applications of IMS	85
The protein microscope.....	86
Automation and robotics in proteomics	86
Laser capture microdissection	87
Microdissection techniques used for proteomics	87
Uses of LCM in combination with proteomic technologies	87
Concluding remarks about applications of proteomic technologies.....	88
Precision proteomics	88
3. Protein biochip technology	90
Introduction	90
Types of protein biochips.....	91
ProteinChip	91
<i>Applications and advantages of ProteinChip.....</i>	<i>92</i>
<i>ProteinChip Biomarker System</i>	<i>92</i>
<i>Matrix-free ProteinChip Array</i>	<i>93</i>
Aptamer-based protein biochip	93
Fluorescence planar wave guide technology-based protein biochips.....	94
Lab-on-a-chip for protein analysis.....	94
Microfluidic biochips for proteomics	95
Protein biochips for high-throughput expression.....	96
<i>Nucleic Acid-Programmable Protein Array.....</i>	<i>96</i>
<i>High-density protein microarrays</i>	<i>96</i>
<i>HPLC-Chip for protein identification</i>	<i>96</i>
<i>Antibody microarrays</i>	<i>97</i>
<i>Integration of protein array and image analysis</i>	<i>97</i>
Tissue microarray technology for proteomics	97
Protein biochips in molecular diagnostics.....	98
A force-based protein biochip	99
L1 chip and lipid immobilization	99
Multiplexed Protein Profiling on Microarrays.....	99
Live cell microarrays.....	100
ProteinArray Workstation	100
Proteome arrays	101
The Yeast ProtoArray.....	101
ProtoArray™ Human Protein Microarray	101
TRINECTIN proteome chip.....	102
Peptide arrays	102
Surface plasmon resonance technology	103
Biacore's SPR	103
FLEX CHIP.....	103
Combination of surface plasmon resonance and MALDI-TOF	104
Protein chips/microarrays using nanotechnology.....	104
Nanoparticle protein chip	104
Protein nanobiochip.....	104
Protein nanoarrays.....	105
Self-assembling protein nanoarrays.....	105
Companies involved in protein biochip/microarray technology	106
4. Bioinformatics in Relation to Proteomics	110
Introduction	110
Bioinformatic tools for proteomics.....	110
Testing of SELDI-TOF MS Proteomic Data.....	110
BioImagine's ProteinMine	111
Bioinformatics for pharmaceutical applications of proteomics.....	111
<i>In silico</i> search of drug targets by Biopendium.....	<i>111</i>
Compugen's LEADS	112
DrugScore.....	112
Proteochemometric modeling	112
Integration of genomic and proteomic data.....	113
Proteomic databases: creation and analysis	114
Introduction	114
Proteomic databases	114

<i>GenProtEC</i>	115
<i>Human Protein Atlas</i>	115
<i>Human Proteomics Initiative</i>	116
<i>International Protein Index</i>	117
<i>Proteome maps</i>	117
<i>Protein Structure Initiative – Structural Genomics Knowledgebase</i>	117
<i>Protein Warehouse Database</i>	117
<i>Protein Data Bank</i>	118
<i>Universal Protein Resource</i>	118
Protein interaction databases	118
<i>Biomolecular Interaction Network Database</i>	119
ENCODE	119
<i>Functional Genomics Consortium</i>	120
<i>Human Proteinpedia</i>	120
<i>ProteinCenter</i>	120
<i>Databases of the National Center for Biotechnology Information</i>	121
Bioinformatics for protein identification	121
Application of bioinformatics in functional proteomics	121
Use of bioinformatics in protein sequencing	122
Bottom-up protein sequencing.....	122
Top-down protein sequencing.....	123
Protein structural database approach to drug design	123
Bioinformatics for high-throughput proteomics	124
Companies with bioinformatic tools for proteomics	125
5. Research in Proteomics	126
Introduction	126
Applications of proteomics in biological research	126
Identification of novel human genes by comparative proteomics	126
Study of relationship between genes and proteins.....	127
Characterization of histone codes.....	127
Structural genomics or structural proteomics	128
Protein Structure Factory	129
Protein Structure Initiative	129
Studies on protein structure at Argonne National Laboratory	130
Structural Genomics Consortium.....	130
Protein knockout	131
Antisense approach and proteomics	131
RNAi and protein knockout.....	131
Total knockout of cellular proteins.....	131
Ribozymes and proteomics	132
Single molecule proteomics	132
Single-molecule photon stamping spectroscopy	132
Single nucleotide polymorphism determination by TOF-MS.....	133
Application of proteomic technologies in systems biology	133
Signaling pathways and proteomics.....	133
Kinomics.....	134
Combinatorial RNAi for quantitative protein network analysis	134
Proteomics in neuroscience research	134
Stem cell proteomics	135
hESC phosphoproteome.....	135
Proteomic studies of mesenchymal stem cells.....	136
Proteomics of neural stem cells.....	136
Proteome Biology of Stem Cells Initiative	137
Proteomic analysis of the cell cycle	138
Nitric oxide and proteomics	138
A proteomic method for identification of cysteine S-nitrosylation sites	138
Study of the nitroproteome	138
Study of the phosphoproteome	139
Study of the mitochondrial proteome	139
Proteomic technologies for study of mitochondrial proteomics	140
Cryptome	140
Study of protein transport in health and disease	140
Proteomics research in the academic sector	141
Vanderbilt University's Center for Proteomics and Drug Actions	143
ProteomeBinders initiative.....	143
Rutgers University's Center for Integrative Proteomics Research.....	143
6. Pharmaceutical Applications of Proteomics	144
Introduction	144
Current drug discovery process and its limitations	144

Role of omics in drug discovery	145
Genomics-based drug discovery.....	145
Metabolomics technologies for drug discovery	146
Role of metabolomics in drug discovery	146
Basis of proteomics approach to drug discovery	147
<i>Proteins and drug action</i>	<i>147</i>
<i>Transcription-aided drug design.....</i>	<i>148</i>
Role of proteomic technologies in drug discovery	148
<i>Liquid chromatography-based drug discovery</i>	<i>149</i>
<i>Capture compound mass spectrometry</i>	<i>150</i>
<i>Protein-expression mapping by 2DGE.....</i>	<i>150</i>
<i>Role of MALDI mass spectrometry in drug discovery.....</i>	<i>150</i>
<i>Tissue imaging mass spectrometry.....</i>	<i>150</i>
<i>Companies using MALDI for drug discovery</i>	<i>152</i>
Oxford Genome Anatomy Project	152
Proteins as drug targets.....	153
Ligands to capture the purine binding proteome	153
Chemical probes to interrogate key protein families for drug discovery	153
Global proteomics for pharmacodynamics	154
CellCarta® proteomics platform.....	154
ZeptoMARK™ protein profiling system	155
Role of proteomics in targeting disease pathways	155
Identification of protein kinases as drug targets.....	155
<i>Mechanisms of action of kinase inhibitors.....</i>	<i>156</i>
G-protein coupled receptors as drug targets.....	156
<i>Methods of study of GPCRs.....</i>	<i>157</i>
<i>Cell-based assays for GPCR.....</i>	<i>157</i>
<i>Companies involved in GPCR-based drug discovery</i>	<i>158</i>
<i>GPCR localization database</i>	<i>159</i>
Matrix metalloproteases as drug targets	159
PDZ proteins as drug targets.....	160
Proteasome as drug target.....	160
Serine hydrolases as drug targets	161
Targeting mTOR signaling pathway	161
Targeting caspase-8 for anticancer therapeutics	162
Bioinformatic analysis of proteomics data for drug discovery	163
Drug design based on structural proteomics.....	163
Protein crystallography for determining 3D structure of proteins	163
Automated 3D protein modeling	164
<i>Drug targeting of flexible dynamic proteins</i>	<i>164</i>
Companies involved in structure-based drug-design	164
Integration of genomics and proteomics for drug discovery	165
Ligand-receptor binding	166
Role of proteomics in study of ligand-receptor binding	166
Aptamer protein binding	167
<i>Systematic Evolution of Ligands by Exponential Enrichment</i>	<i>167</i>
<i>Aptamers and high-throughput screening.....</i>	<i>167</i>
<i>Nucleic Acid Biotools.....</i>	<i>168</i>
<i>Aptamer beacons.....</i>	<i>168</i>
<i>Peptide aptamers.....</i>	<i>169</i>
Riboreporters for drug discovery	169
Target identification and validation	169
Application of mass spectrometry for target identification	170
Gene knockout and gene suppression for validating protein targets.....	170
Laser-mediated protein knockout for target validation	170
Integrated proteomics for drug discovery	171
High-throughput proteomics.....	171
Companies involved in high-throughput proteomics.....	172
Drug discovery through protein-protein interaction studies	172
Protein-protein interaction as basis for drug target identification	173
Protein-PCNA interaction as basis for drug design	173
Two-hybrid protein interaction technology for target identification	174
Biosensors for detection of small molecule-protein interactions.....	174
Protein-protein interaction maps.....	175
<i>ProNet (Myriad Genetics)</i>	<i>175</i>
<i>Hybrigenics' maps of protein-protein interactions.....</i>	<i>175</i>
<i>CellZome's functional map of protein-protein interactions</i>	<i>176</i>
Mapping of protein-protein interactions by mass spectrometry.....	176
Protein interaction map of Drosophila melanogaster	177
Protein-interaction map of Wellcome Trust Sanger Institute	177
Protein-protein interactions as targets for therapeutic intervention.....	177

Inhibition of protein-protein interactions by peptide aptamers	178
Selective disruption of proteins by small molecules	178
Post-genomic combinatorial biology approach	178
Differential proteomics	179
Shotgun proteomics.....	179
Chemogenomics/chemoproteomics for drug discovery	180
<i>Chemoproteomics-based drug discovery</i>	<i>181</i>
<i>Companies involved in chemogenomics/chemoproteomics</i>	<i>182</i>
<i>Activity-based proteomics</i>	<i>183</i>
<i>Locus Discovery technology.....</i>	<i>183</i>
<i>Automated ligand identification system.....</i>	<i>184</i>
Expression proteomics: protein level quantification	184
Role of phage antibody libraries in target discovery	185
Analysis of posttranslational modification of proteins by MS	185
Phosphoproteomics for drug discovery	186
Application of glycoproteomics for drug discovery	186
Role of carbohydrates in proteomics.....	186
Challenges of glycoproteomics.....	187
Companies involved in glycoproteomics	187
Role of protein microarrays/ biochips for drug discovery	188
Protein microarrays vs DNA microarrays for high-throughput screening	188
BIA-MS biochip for protein-protein interactions.....	188
ProteinChip with Surface Enhanced Neat Desorption.....	189
Protein-domains microarrays.....	189
Some limitations of protein biochips	189
Concluding remarks about role of proteomics in drug discovery.....	190
RNA versus protein profiling as guide to drug development	190
RNA as drug target	190
Combination of RNA and protein profiling	191
<i>RNA binding proteins.....</i>	<i>192</i>
Toxicoproteomics.....	192
Hepatotoxicity	192
Nephrotoxicity	193
Cardiotoxicity	193
Neurotoxicity.....	194
Protein/peptide therapeutics.....	194
Peptide-based drugs.....	194
Phylomer [®] peptides.....	195
Cryptein-based therapeutics.....	195
Synthetic proteins and peptides as pharmaceuticals	196
Genetic immunization and proteomics	196
Proteomics and gene therapy	197
Role of proteomics in clinical drug development.....	197
Pharmacoproteomics	197
Role of proteomics in clinical drug safety.....	198

7. Application of Proteomics in Human Healthcare	200
Introduction	200
Clinical proteomics	201
Definition and standards	201
Vermillion's Clinical Proteomics Program	201
Pathophysiology of human diseases	202
Diseases due to misfolding of proteins.....	202
<i>Mechanism of protein folding.....</i>	<i>203</i>
<i>Nanoproteomics for study of misfolded proteins.....</i>	<i>204</i>
<i>Therapies for protein misfolding.....</i>	<i>204</i>
Intermediate filament proteins	205
Significance of mitochondrial proteome in human disease	206
<i>Proteome of Saccharomyces cerevisiae mitochondria.....</i>	<i>206</i>
<i>Rat mitochondrial proteome</i>	<i>206</i>
Proteomic approaches to biomarker identification.....	207
The ideal biomarker	207
Proteomic technologies for biomarker discovery.....	207
<i>MALDI mass spectrometry for biomarker discovery</i>	<i>208</i>
<i>BAMFTM Technology</i>	<i>208</i>
Protein biochips/microarrays and biomarkers	209
Antibody-based biomarker discovery	209
Tumor-specific serum peptidome patterns.....	209
Search for protein biomarkers in body fluids.....	210
Challenges and strategies for discovery of protein biomarkers in plasma.....	210
<i>3-D structure of CD38 as a biomarker</i>	<i>211</i>

<i>BD™ Free Flow Electrophoresis System</i>	211
<i>Isotope tags for relative and absolute quantification</i>	212
<i>N-terminal peptide isolation from human plasma</i>	212
<i>Plasma protein microparticles as biomarkers</i>	212
<i>Proteome partitioning</i>	213
<i>SISCAPA method for quantitating proteins and peptides in plasma</i>	213
<i>Stable isotope tagging methods</i>	213
<i>Technology to measure both the identity and size of the biomarker</i>	214
Biomarkers in the urinary proteome	214
Application of proteomics in molecular diagnosis	215
Proximity ligation assay	216
Protein patterns	216
Proteomic tests on body fluids	216
Cyclical amplification of proteins	218
Applications of proteomics in infections	218
Mass spectrometry for microbial identification	218
Role of proteomics in virology	219
<i>Study of interaction of proteins with viruses</i>	219
Role of proteomics in bacteriology	219
<i>Epidemiology of bacterial infections</i>	220
<i>Proteomic approach to bacterial pathogenesis</i>	220
<i>Vaccines for bacterial infections</i>	220
<i>Protein profiles associated with bacterial drug resistance</i>	221
Analyses of the parasite proteome	221
Application of proteomics in cystic fibrosis	222
Proteomics of cardiovascular diseases	222
Pathomechanism of cardiovascular diseases	222
Study of cardiac mitochondrial proteome in myocardial ischemia	222
Cardiac protein databases	223
Proteomics of dilated cardiomyopathy and heart failure	223
Proteomic biomarkers of cardiovascular diseases	224
Role of proteomics in cardioprotection	224
Role of proteomics in heart transplantation	224
Future of application of proteomics in cardiology	225
Proteomic technologies for research in pulmonary disorders	225
Application of proteomics in renal disorders	226
Diagnosis of renal disorders	226
Proteomic biomarkers of acute kidney injury	227
Cystatin C as biomarker of glomerular filtration rate	227
Protein biomarkers of nephritis	227
Proteomics and kidney stones	228
Proteomics of eye disorders	228
Proteomics of cataract	228
Proteomics of diabetic retinopathy	229
Retinal dystrophies	229
Use of proteomics in inner ear disorders	230
Use of proteomics in aging research	230
Removal of altered cellular proteins in aging	231
Alteration of glycoproteins during aging	231
Proteomics and nutrition	231
8. Oncoproteomics	232
Introduction	232
Proteomic technologies for study of cancer	233
Application of CellCarta technology for oncology	233
Accentuation of differentially expressed proteins using phage technology	233
Identification of oncogenic tyrosine kinases using phosphoproteomics	233
Single-cell protein expression analysis by microfluidic techniques	234
<i>Dynamic cell proteomics in response to a drug</i>	234
Desorption electrospray ionization for cancer diagnosis	234
Proteomic analysis of cancer cell mitochondria	235
Mass spectrometry for identification of oncogenic chimeric proteins	235
Id proteins as targets for cancer therapy	236
Proteomic study of p53	236
Human Tumor Gene Index	236
Integration of cancer genomics and proteomics	237
Laser capture microdissection technology and cancer proteomics	237
Cancer tissue proteomics	238
Use of proteomics in cancers of various organ systems	238
Proteomics of brain tumors	238
Proteomics of breast cancer	239

Proteomics of colorectal cancer.....	241
Proteomics of esophageal cancer	241
Proteomics of hepatic cancer	241
Proteomics of leukemia.....	242
Proteomics of lung cancer	243
Proteomics of pancreatic cancer.....	243
Proteomics of prostate cancer.....	243
Diagnostic use of cancer biomarkers	244
Proteomic technologies for tumor biomarkers	245
Nuclear matrix proteins (NMPs)	245
Antiannexins as tumor markers in lung cancer.....	246
NCI's Network of Clinical Proteomic Technology Centers.....	246
Proteomics and tumor immunology	247
Proteomics and study of tumor invasiveness	248
Anticancer drug discovery and development	248
Kinase-targeted drug discovery in oncology.....	248
Anticancer drug targeting: functional proteomics screen of proteases	249
Small molecule inhibitors of cancer-related proteins	249
Role of proteomics in studying drug resistance in cancer.....	250
Future prospects of oncoproteomics	250
Companies involved in application of proteomics to oncology	250
9. Neuroproteomics	252
Introduction	252
Proteomics of prion diseases	252
Transmissible spongiform encephalopathies	253
<i>Creutzfeldt-Jakob disease</i>	253
<i>Bovine spongiform encephalopathy</i>	254
<i>Variant Creutzfeldt-Jakob disease</i>	254
Protein misfolding and neurodegenerative disorders.....	254
Ion channel link for protein-misfolding disease	254
Detection of misfolded proteins.....	255
Neurodegenerative disorders with protein abnormalities	255
<i>Alzheimer disease</i>	257
<i>Common denominators of Alzheimer and prion diseases</i>	257
<i>Parkinson disease</i>	258
<i>Amyotrophic lateral sclerosis</i>	258
Proteomics and glutamate repeat disorders	259
<i>Proteomics and Huntington's disease</i>	259
Proteomics and demyelinating diseases	260
Proteomics of neurogenetic disorders	260
Fabry disease	260
GM1 gangliosidosis.....	261
Quantitative proteomics and familial hemiplegic migraine	261
Proteomics of spinal muscular atrophy	262
Proteomics of CNS trauma	262
Proteomics of traumatic brain injury.....	262
Chronic traumatic encephalopathy and ALS	263
Proteomics of CNS aging.....	263
Protein aggregation as a biomarker of aging	263
Neuroproteomics of psychiatric disorders.....	264
Neuroproteomic of cocaine addiction	264
Neurodiagnostics based on proteomics.....	265
Disease-specific proteins in the cerebrospinal fluid	265
<i>Tau proteins</i>	266
CNS tissue proteomics	266
Diagnosis of CNS disorders by examination of proteins in urine	268
Diagnosis of CNS disorders by examination of proteins in the blood.....	268
<i>Serum pNF-H as biomarker of CNS damage</i>	269
Proteomics of BBB	269
Future prospects of neuroproteomics in neurology.....	270
HUPO's Pilot Brain Proteome Project.....	271
10. Commercial Aspects of Proteomics	272
Introduction	272
Potential markets for proteomic technologies	272
Geographical distribution of proteomics technologies markets	273
Markets for protein separation technologies	273
<i>Markets for 2D gel electrophoresis</i>	274
<i>Trends in protein separation technologies and effect on market</i>	274
Protein biochip markets	274

Mass spectrometry markets	275
Markets for MALDI for drug discovery	275
Markets for nuclear magnetic resonance spectroscopy	275
Market for structure-based drug design	276
Bioinformatics markets for proteomics	276
Markets for protein biomarkers	276
Markets for cell-based protein assays	276
Business and strategic considerations	277
Cost of protein structure determination	277
Opinion surveys of the scientist consumers of proteomic technologies	277
<i>Opinions on mass spectrometry</i>	277
<i>Opinions on bioinformatics and proteomic databases</i>	277
<i>Systems for in vivo study of protein-protein interactions</i>	278
<i>Perceptions of the value of protein biochip/microfluidic systems</i>	278
Small versus big companies	278
Expansion in proteomics according to area of application	278
Growth trends in cell-based protein assay market	279
<i>Challenges for development of cell-based protein assays</i>	279
<i>Future trends and prospects of cell-based protein assays</i>	279
Strategic collaborations	280
<i>Analysis of proteomics collaborations according to types of companies</i>	280
<i>Types of proteomic collaborations</i>	281
<i>Proteomics collaborations according to application areas</i>	281
<i>Analysis of proteomics collaborations: types of technologies</i>	281
<i>Collaborations based on protein biochip technology</i>	282
<i>Concluding remarks about proteomic collaborations</i>	282
Proteomic patents	283
Market drivers in proteomics	283
Needs of the pharmaceutical industry	283
Need for outsourcing proteomic technologies	284
Funding of proteomic companies and research	284
Technical advances in proteomics	284
Changing trends in healthcare in future	285
Challenges facing proteomics	285
Magnitude and complexity of the task	285
Technical challenges	285
Limitations of proteomics	286
<i>Limitations of 2DGE</i>	286
<i>Limitations of mass spectrometry techniques</i>	286
<i>Complexity of the pharmaceutical proteomics</i>	286
Unmet needs in proteomics	287
11. Future of Proteomics	288
Genomics to proteomics	288
Faster technologies	288
FLEXGene repository	288
Need for new proteomic technologies	289
Emerging proteomic technologies	290
Detection of alternative protein isoforms	290
Direct protein identification in large genomes by mass spectrometry	290
Proteome identification kits with stacked membranes	290
Vacuum deposition interface	291
<i>In vitro</i> protein biosynthesis	291
Proteome mining with adenosine triphosphate	291
Proteome-scale purification of human proteins from bacteria	291
Proteostasis network	292
Cytoproteomics	292
<i>Subcellular proteomics</i>	292
<i>Individual cell proteomics</i>	293
<i>Live cell proteomics</i>	293
<i>Fluorescent proteins for live-cell imaging</i>	294
Membrane proteomics	294
<i>Identification of membrane proteins by tandem MS of protein ions</i>	294
<i>Solid state NMR for study of nanocrystalline membrane proteins</i>	295
Multiplex proteomics	295
High-throughput for proteomics	295
Future directions for protein biochip application	296
Bioinformatics for proteomics	296
High-Throughput Crystallography Consortium	296
Study of protein folding by IBM's Blue Gene	297
Study of proteins by atomic force microscopy	297

Population proteomics	297
Comparative proteome analysis	298
Human Proteome Organization	298
Human Salivary Proteome	299
Academic-commercial collaborations in proteomics	299
Indiana Centers for Applied Protein Sciences	299
Role of proteomics in the healthcare of the future.....	300
Proteomics and molecular medicine.....	300
Proteodiagnosics.....	300
Proteomics and personalized medicine.....	301
<i>Targeting the ubiquitin pathway for personalized therapy of cancer.....</i>	<i>301</i>
<i>Protein patterns and personalized medicine.....</i>	<i>301</i>
<i>Personalizing interferon therapy of hepatitis C virus</i>	<i>303</i>
<i>Protein biochips and personalized medicine</i>	<i>303</i>
<i>Combination of diagnostics and therapeutics</i>	<i>304</i>
<i>Future prospects.....</i>	<i>304</i>

12. References..... 306

Tables

Table 1-1: Landmarks in the evolution of proteomics	18
Table 1-2: Comparison of DNA and protein	27
Table 1-3: Comparison of mRNA and protein.....	27
Table 1-4: Methods of analysis at various levels of functional genomics	33
Table 2-1: Proteomics technologies.....	36
Table 2-2: Protein separation technologies of selected companies	41
Table 2-3: Companies supplying mass spectrometry instruments	43
Table 2-4: Companies involved in cell-based protein assays	66
Table 2-5: Methods used for the study of protein-protein interactions	68
Table 2-6: A selection of companies involved in protein-protein interaction studies	74
Table 2-7: Proteomic technologies used with laser capture microdissection	88
Table 3-1: Applications of protein biochip technology	90
Table 3-2: Selected companies involved in protein biochip/microarray technology	106
Table 4-1: Proteomic databases and other Internet sources of proteomics information	114
Table 4-2: Protein interaction databases available on the Internet	119
Table 4-3: Bioinformatic tools for proteomics from academic sources	124
Table 4-4: Selected companies involved in bioinformatics for proteomics.....	125
Table 5-1: Applications of proteomics in basic biological research	126
Table 5-2: A sampling of proteomics research projects in academic institutions	141
Table 6-1: Pharmaceutical applications of proteomics.....	144
Table 6-2: Selected companies relevant to MALDI-MS for drug discovery.....	152
Table 6-3: Selected companies involved in GPCR-based drug discovery	158
Table 6-4: Companies involved in drug design based on structural proteomics	165
Table 6-5: Proteomic companies with high-throughput protein expression technologies	172
Table 6-6: Selected companies involved in chemogenomics/chemoproteomics	182
Table 6-7: Companies involved in glycoproteomic technologies	187
Table 7-1: Applications of proteomics in human healthcare	200
Table 7-2: Eye disorders and proteomic approaches.....	228
Table 8-1: Companies involved in applications of proteomics to oncology	251
Table 9-1: Neurodegenerative diseases with underlying protein abnormality	255
Table 9-2: Disease-specific proteins in the cerebrospinal fluid of patients.....	265
Table 10-1: Potential markets for proteomic technologies 2011-2021.....	272
Table 10-2: Geographical distribution of markets for proteomic technologies 2011-2021	273
Table 10-3: 2011 revenues of major companies from protein separation technologies	273
Table 11-1: Role of proteomics in personalizing strategies for cancer therapy	301

Figures

Figure 1-1: A schematic miRNA pathway	21
Figure 1-2: Relationship of DNA, RNA and protein in the cell.....	28
Figure 1-3: Protein production pathway from gene expression to functional protein with controls.	30
Figure 1-4: Parallels between functional genomics and proteomics.....	31
Figure 2-1: Proteomics: flow from sample preparation to characterization.....	37
Figure 2-2: The central role of spectrometry in proteomics	43
Figure 2-3: Electrospray ionization (ESI)	44
Figure 2-4: Matrix-Assisted Laser Desorption/Ionization (MALDI).....	45
Figure 2-5: Scheme of bio-bar-code assay	61
Figure 2-6: A diagrammatic presentation of yeast two-hybrid system.....	69
Figure 3-1: ProteinChip System	92
Figure 3-2: Surface plasma resonance (SPR).....	103
Figure 4-1: Role of bioinformatics in integrating genomic/proteomic-based drug discovery	113
Figure 4-2: Bottom-up and top-down approaches for protein sequencing	122

Figure 6-1: Drug discovery process.....	145
Figure 6-2: Regulatory changes induced by drugs and implemented at the proteins level.	148
Figure 6-3: Relation of proteome to genome, diseases and drugs	149
Figure 6-4: The mTOR pathways	162
Figure 6-5: Steps in shotgun proteomics	180
Figure 6-6: Chemogenomic approach to drug discovery (3-Dimensional Pharmaceuticals)	181
Figure 8-1: Relation of oncoproteomics to other technologies	232
Figure 9-1: A scheme of proteomics applications in CNS drug discovery and development	271
Figure 10-1: Types of companies involved in proteomics collaborations	280
Figure 10-2: Types of collaborations: R & D, licensing or marketing	281
Figure 10-3: Proteomics collaborations according to application areas	281
Figure 10-4: Proteomics collaborations according to technologies	282
Figure 10-5: Unmet needs in proteomics	287
Figure 11-1: A scheme of the role of proteomics in personalized management of cancer.....	303